ExpandOne in Twenty Diagnosed with Secondary Cancer One Year After CAR T-Cell Therapy
5.2% of patients who have undergone CAR T-cell therapy develop secondary cancer within a year, including both metastatic cancers and second primary cancers, with small variations by medication.


















